This activity is expired and is no longer available for CME credit.


Updates in the Management of Wet Macular Degeneration

Author(s)/Faculty: Andrew A. Moshfeghi, MD; Carmen A. Puliafito, MD, MBA; Michael W. Stewart, MD; Philip J. Rosenfeld, MD, PhD
Release Date: 3/16/2012Expiration Date: 3/15/2015
Credit Type: CME / ParticipationNumber of Credits: 0
Content Type: Provider:
The availability of intravitreal pharmacotherapy to reverse the destructive changes caused by neovascular age related macular degeneration has been a transformative event. Whereas earlier therapeutic approaches sacrifi ced critical retinal structures to preserve an island of central vision, the introduction of VEGF inhibitors has elevated outcomes and patient expectations. Understanding the mechanism of action of these novel molecules and following provide evidence-based guidelines regarding their optimal administration will offer patients the best visual outcomes. Applying data from recent pivotal clinical trials that compare the effectiveness and durability of these innovative agents, and appropriately implementing optical coherence tomography to monitor disease progression and treatment efficacy are also critical in allowing clinicians to apply solutions that restore anatomic and visual function.